Trial · NCT01199302
Results by group200
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 200
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo / Brodalumab 350 mg | All treatment-emergent adverse events (TEAEs) | 14 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg / 350 mg | All treatment-emergent adverse events (TEAEs) | 12 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg / 350 mg | All treatment-emergent adverse events (TEAEs) | 18 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodaluamb 700 mg / 350 mg | All treatment-emergent adverse events (TEAEs) | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo / Brodalumab 350 mg | Serious adverse events | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg / 350 mg | Serious adverse events | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg / 350 mg | Serious adverse events | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodaluamb 700 mg / 350 mg | Serious adverse events | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo / Brodalumab 350 mg | Fatal adverse events | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg / 350 mg | Fatal adverse events | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg / 350 mg | Fatal adverse events | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodaluamb 700 mg / 350 mg | Fatal adverse events | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo / Brodalumab 350 mg | TEAEs leading to discontinuation of study drug | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg / 350 mg | TEAEs leading to discontinuation of study drug | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg / 350 mg | TEAEs leading to discontinuation of study drug | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodaluamb 700 mg / 350 mg | TEAEs leading to discontinuation of study drug | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo / Brodalumab 350 mg | TEAEs leading to discontinuation from study | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg / 350 mg | TEAEs leading to discontinuation from study | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg / 350 mg | TEAEs leading to discontinuation from study | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodaluamb 700 mg / 350 mg | TEAEs leading to discontinuation from study | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01199302/results